

Title Suggestions:

Importance of accurate *EPCAM* deletion characterization to prevent misdiagnosis of Lynch syndrome

Authors: Carolyn Horton, Rebecca Mar-Heyming, Felicia Hernandez, Ashley P.L. Marsh, Steven Harrison, Jessica Grzybowski, Marcy E. Richardson, Daniel Kostecki, Christopher Lau, Elizabeth Chao & Heather Hampel

Background and Aim

Gross deletions involving the 3' end of *EPCAM* cause Lynch syndrome (LS). Prior to the introduction of NGS, *EPCAM* deletion screening was typically performed by one MLPA kit throughout the country, in which the 5'-most probe resides in exon 3. Therefore, it can be unclear whether some deletions encompass the full gene. However, full *EPCAM* deletions may not be disease-causing so accurate differentiation of deletion size has significant clinical implications.

Methods

We reviewed cases with a gross deletion of *EPCAM* identified at a single laboratory from 2011-2021 to determine how many had a known or possible full *EPCAM* deletion detected via MLPA or microarray. Amsterdam criteria II (AC) and revised Bethesda criteria (BC) were assessed in families with full and partial deletions. Data presented herein are exempt from IRB review.

Results

A total of 349 cases were identified that included an *EPCAM* deletion, 246 of which also included *MSH2*. Isolated *EPCAM* deletions were identified in 103 individuals from 65 unique families. In most families (72.3%; 47/65), MLPA indicated a partial *EPCAM* deletion based on retention of the exon 3 probe. In 9 additional families (13.9% of 65), 5'UTR coverage from a microarray was available and identified a full *EPCAM* deletion. Deletion size could not be determined in 9 remaining families (13.9%). Therefore, a quarter (27.7%) of families with *EPCAM* deletions identified at our laboratory have a known or possible full gene deletion. No families with a known full gene deletion met AC and 1 met BC while 44.7% (n=21) and 89.3% (n=42) of those with a partial deletion met AC or BC, respectively.

Conclusions

This study identifies a need for re-evaluation of a subset of individuals with *EPCAM* deletions and supports findings that full *EPCAM* deletions are not pathogenic. Accurate characterization of *EPCAM* deletions is critical to prevent misdiagnosis of LS.

Keywords: 1-6 keywords

Lynch syndrome

MLPA

EPCAM

Diagnostic testing

Misdiagnosis

Colorectal cancer